

Sheet 1 of 1FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
896034605001SERIAL NO.  
09/966,264INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT

Elizabeth K. Barber

FILING DATE

September 28, 2001

GROUP

~~1631~~ 1636

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/SUBCLASS	FILING DATE
---------------------	--------------------	------	------	----------------	-------------

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
---------------------	-----------------	------	---------	-------	----------	-----------------------

EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
---------------------	-----------------	--

*sk* Atkinson, J. and R. Martin. Mutations to nonsense codons in human genetic disease: implications for gene therapy by nonsense suppressor tRNAs. *Nucleic Acids Research* 22(8), 1327-1334 (1994).

*sk* Buvoli, M. et al. Suppression of nonsense mutations in cell culture and mice by multimerized suppressor tRNA genes. *Molecular and Cellular Biology* 20(9), 3116-3124 (May 2000).

*sk* Kaufman, Randal J. Correction of genetic disease by making sense from nonsense. *Journal of Clinical Investigation* 104(4), 367-368 (August 1999).

*sk* Kessler, P.D. et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. *PNAS USA* 93, 14082-14087 (1996).

*sk* Kidwell M.G. and A.R. Wattam. An important step forward in the genetic manipulation of mosquito vectors of human disease. *PNAS* 95(7), 3349-3350 (March 1998).

*sk* Haecker, S.E. et al. *In vivo* expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. *Human Gene Therapy* 7, 1907-1914 (1996).

*sk* Miralles, V.J. et al. The adenovirus inverted terminal repeat functions as an enhancer in a cell-free system. *J. Biol. Chem.* 264(18), 10763-10772 (1989).

*sk* Passos-Bueno, M.R. et al. Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. *Human Molecular Genetics* 3(6), 919-922 (1994).

*sk* Proudfoot, N.J. Transcriptional interference and termination between duplicated  $\beta$ -globin gene constructs suggests a novel mechanism for gene regulation. *Nature* 322, 562-565 (1986).

*sk* Stedman, H. et al. Clinical protocol: phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy:  $\square$ ,  $\square$ ,  $\square$ ,  $\square$ -sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. *Human Gene Therapy* 11, 777-790 (March 2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/088 (04-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number 09/966,264  
Filing Date 9/28/2001  
First Named Inventor Elizabeth K. Barber  
Art Unit 1631  
Examiner Name Mary K. Zeman  
Attorney Docket Number 896034605001

RECEIVED

MAY 08 2003

TECH CENTER 1600/2900

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SE		BARBER, E.K., DASGUPTA, J.D., SHLOSSMAN, S.F., TREVILLYAN, J.M., and RUDD, C.E. The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex. Proc. Natl. Acad. Sci. USA., 86: 3277-3281 (1989).	
SE		BROWN, S.C., and LUCY, J.A. Dystrophin as a Mechanochemical Transducer in Skeletal Muscle. BioEssays, 15: 413-419 (1993).	
SE		KOENIG, M., BEGGS, A.H., MOYER, M., SCHERPF, S., HEINDRICH, K., BETTECKEN, T., MENG, G., et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet., 45: 498-506 (1989).	
SE		RAPAPORT, D., FUCHS, O., NUDEL, U., and YAFFE, D. Expression of the Duchenne muscular dystrophy gene products in embryonic stem cells and their differentiated derivatives. J. Biol. Chem., 267: 21289-21292 (1992).	
SE		SMITH, L.J., CURTIS, J.E., MESSNER, H.A., SENN, J.S., FURTHMAYR, H., and MCCULLOCH, E.A. Lineage infidelity in acute leukemia. Blood, 61: 1138-1145 (1983).	
SE		TINSLEY, J.M., BLAKE, D., and DAVIES, K.E. Apo-dystrophin-3: a 2.2 kb transcript from the DMD locus encoding the dystrophin glycoprotein binding site. Human Mol. Genet., 2: 521-524 (1993).	
SE		VORONOVA, A.F., and SEFTON, B.M. Expression of a new tyrosine protein kinase is stimulated by retrovirus promoter insertion. Nature, 319: 682-685 (1986).	

Examiner Signature		Date Considered	4/13/04
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.